Pharmacokinetics and pharmacodynamics of hydroxyurea

被引:89
作者
Gwilt, PR
Tracewell, WG
机构
[1] MDS Harris, Lincoln, NE 68502 USA
[2] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE USA
关键词
D O I
10.2165/00003088-199834050-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hydroxyurea is used in the treatment of various forms of cancer, sickle-cell anaemia and HIV infection. Oral absorption of the drug is virtually complete, the volume of distribution is equivalent to total body water and elimination is through both renal and nonrenal mechanisms, Nonrenal elimination of hydroxyurea is characterised by Michaelis-Menten kinetics. Further studies are necessary to clarify several aspects of the pharmacokinetics and pharmacodynamics of hydroxyurea: the effect of age and disease state, concentration-effect relationship, the role of therapeutic drug monitoring, and the mechanisms of renal and nonrenal elimination. The recent development of improved assays for hydroxyurea should have benefits for future pharmacokinetic studies.
引用
收藏
页码:347 / 358
页数:12
相关论文
共 82 条
[71]   POPULATION PHARMACOKINETICS OF HYDROXYUREA IN CANCER-PATIENTS [J].
TRACEWELL, WG ;
TRUMP, DL ;
VAUGHAN, WP ;
SMITH, DC ;
GWILT, PR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (05) :417-422
[72]  
Tracewell William G., 1992, Pharmaceutical Research (New York), V9, pS260
[73]   PHARMACOKINETICS OF HYDROXYUREA IN NUDE-MICE [J].
VANDENBERG, CL ;
MCGILL, JR ;
KUHN, JG ;
WALSH, JT ;
DELACRUZ, PS ;
DAVIDSON, KK ;
WAHL, GM ;
VONHOFF, DD .
ANTI-CANCER DRUGS, 1994, 5 (05) :573-578
[74]   PHASE I/II STUDY INCORPORATING INTRAVENOUS HYDROXYUREA INTO HIGH-DOSE CHEMOTHERAPY FOR PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED AND REFRACTORY INTERMEDIATE-GRADE AND HIGH-GRADE MALIGNANT-LYMPHOMA [J].
VAUGHAN, WP ;
KRIS, E ;
VOSE, J ;
BIERMAN, PJ ;
GWILT, P ;
ARMITAGE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1089-1095
[75]  
VEALE D, 1988, CANCER CHEMOTH PHARM, V21, P53
[76]   1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection [J].
Vila, J ;
Biron, F ;
Nugier, F ;
Vallet, T ;
Peyramond, D .
LANCET, 1996, 348 (9021) :203-204
[77]   Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I [J].
Villani, P ;
Maserati, R ;
Regazzi, MB ;
Giacchino, R ;
Lori, F .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (02) :117-121
[78]  
VONHOFF DD, 1991, CANCER RES, V51, P6273
[79]   COMPARATIVE DISTRIBUTION AND EMBRYOTOXICITY OF HYDROXYUREA IN PREGNANT RATS AND RHESUS-MONKEYS [J].
WILSON, JG ;
SCOTT, WJ ;
RITTER, EJ ;
FRADKIN, R .
TERATOLOGY, 1975, 11 (02) :169-178
[80]   REGULATION AND DRUG-RESISTANCE MECHANISMS OF MAMMALIAN RIBONUCLEOTIDE REDUCTASE, AND THE SIGNIFICANCE TO DNA-SYNTHESIS [J].
WRIGHT, JA ;
CHAN, AK ;
CHOY, BK ;
HURTA, RAR ;
MCCLARTY, GA ;
TAGGER, AY .
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1990, 68 (12) :1364-1371